Email this article to a friend
A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab
-
* Corresponding author: Pierre Miossec miossec@univ-lyon1.fr
Arthritis Research & Therapy 2007, 9:R61 doi:10.1186/ar2219
See related editorial by Sambrook, http://arthritis-research.com/content/9/4/107